A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

NCT00543712 | Terminated Phase 2

• 1 other identifier: APM4171g
• Study Type: interventional
• Target: 15
• Locations: 2 countries
• Sites: 4

Brief Summary

This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.

Conditions

Chondrosarcoma

Keywords

Sarcoma; synovial sarcoma; APM4171g

Outcome Measures

Primary Outcomes (3)

• Adverse events

• Change in vital signs before and after PRO95780 infusions; clinical laboratory evaluations

• Objective response

Secondary Outcomes (4)

• Duration of objective response

• Progression-free survival

• Overall survival

• Pharmacokinetic parameters

Study Arms (1)

PRO95780

EXPERIMENTAL

Drug: PRO95780

Interventions

PRO95780 DRUG

Intravenous repeating dose

PRO95780

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to understand and willingness to sign a written informed consent document
• Age ≥ 18 years
• Histologic diagnosis of chondrosarcoma, verifiable after enrollment
• Measurable disease
• Previously treated or incurable disease without options for standard of care therapy
• ECOG performance status of 0-2
• Life expectancy of \> 3 months
• For patients of reproductive potential (males and females), use of reliable means for contraception (e.g., contraceptive pill, intrauterine device \[IUD\], physical barrier) throughout the trial and for 1 year following their final exposure to study treatment

You may not qualify if:

• Systemic therapy or radiotherapy within 4 weeks prior to Day 1
• Prior therapy with agents targeting the DR5 apoptosis pathway
• Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to Day 1, or anticipation of need for major surgical procedure during the course of the study
• Other invasive malignancies within 5 years prior to Day 1
• Known active brain metastases
• Uncontrolled intercurrent illness, including but not limited to ongoing or active infection requiring parenteral antibiotics at enrollment
• Clinically significant, symptomatic cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia, Grade II or greater peripheral vascular disease, or history of major heart surgery within 6 months of Day 1, or any situation that would likely limit compliance with study requirements
• Known to be positive for hepatitis C or hepatitis B surface antigen
• History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications
• Use of anticoagulation therapy
• Participation in clinical trials or undergoing other investigational procedures within 30 days prior to Day 1
• Pregnancy or breast feeding
• Known sensitivity to any of the products administered during the study
• Any disorder that compromises the ability of the patient to give written informed consent and/or comply with study procedures

Sponsors & Collaborators

• Genentech, Inc.: lead

Study Sites (4)

Sarcoma Oncology Center

Santa Monica, California, 90403, United States

Location

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

Location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Peter MacCallum Cancer Centre

Melbourne, 3002, Australia

Location

MeSH Terms

Conditions

Chondrosarcoma; Sarcoma; Sarcoma, Synovial

Interventions

drozitumab

Condition Hierarchy (Ancestors)

Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Sandra Skettino, M.D.

  Genentech, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 12, 2007
• First Posted: October 15, 2007
• Study Start: May 31, 2007
• Primary Completion: May 5, 2008
• Study Completion: May 5, 2008
• Last Updated: December 13, 2022

Record last verified: 2022-12

Locations

AU (1); US (3)